PRP Intrauterine Infusion in Thawed Embryo Cycles

Evaluations Clinical Trial

Official title:

Intrauterine Infusion of Platelet-rich Plasma Infusion Before Thawed Embryo Transfer in Repeated Implantation Failure: A Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03734042
• Other study ID #: PRPF
• Status: Completed
• Phase: Phase 4
• Start date: December 1, 2018
• Est. completion date: October 31, 2021

Study information

• Verified date: November 2021
• Source: Tanta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

All patients prepared to thawed embryo transfer were classified into 2 groups one group will receive platelet rich plasma (PRP) infusion intrauterine and the other group will not receive platelet rich plasma (PRP) infusion

Description:

Patients candidates for Thawed embryo transfer with Repeated implantation failure were recruited from 3 centers and classified into 2 groups: Group I: Will receive platelet rich plasma (PRP) intrauterine infusion at day 11 Group II: Not receiving platelet rich plasma (PRP)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: October 31, 2021
• Est. primary completion date: October 31, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• Patients age 20-35 years
• Patients with previous implantation failure
• Patients with thin endometrium<7 mm

Exclusion Criteria:

• Patients older than 40 years
• Patients with fresh embryo transfer
• Patients with abnormal uterine cavity septate, or bicornuate uterus
• Patients with abnormal male factor or tubal factor
• Patients with abnormal embryos grade B or C.
• Patients with immunological disorders as thyroidits or systemic lupus or rheumatoid arthritis

Related Conditions & MeSH terms

• Evaluations

Intervention

Biological:
• Platelet rich plasma intrauterine infusion
platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
• Normal saline
Intrauterine infusion of normal saline at day 11

Locations

Country	Name	City	State
Egypt	Ayman Shehata Dawood	Tanta

Sponsors (1)

Lead Sponsor	Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Endometrial thickness	The increase in endometrial thickness at day of ET	8 days
Primary	Pregnancy rate	Number of cases who got pregnant	15 days